Indian Researchers Call for Balanced and Responsible Research Assessments: Springer Nature Survey Reveals Global Insights
NEW DELHI, June 11, 2025 /PRNewswire/ -- A global survey conducted by Springer Nature reveals that researchers in India are calling for more balanced and responsible approaches to research assessment, with an emphasis on transparency, integrity, and moving beyond over-reliance on quantitative metrics.
The 2024 Research Assessment Survey, which gathered responses from over 6,300 researchers worldwide—including 764 from India—provides important insights into how researchers experience and perceive current evaluation practices. While researchers globally continue to be assessed based on a combination of publication counts, citations, and grant funding, Indian respondents reported a stronger reliance on purely quantitative measures than their global peers.
Notably, 21% of Indian researchers said they are assessed entirely by quantitative metrics such as number of publications, citations, or grant income. This figure is higher than the global average (16%), and even Asia overall (17%). The contrast is particularly striking when compared to the United Kingdom, where only 5% reported being assessed solely on such metrics—reflecting a strong shift in UK research culture toward more holistic evaluations.
At the same time, there is clear appetite for change: 49% of Indian respondents said they believe there should be a balanced mix of quantitative and qualitative criteria in research assessments, suggesting growing interest in reform.
"Researchers in India and globally are sending a clear message—they want assessments that go beyond simplistic metrics like publication counts and journal impact factors," said Dr. Ed Gerstner, Director of Research, Springer Nature. "There is a growing demand for systems that reward openness, collaboration, and real-world impact. At Springer Nature, we are proud to be a driving force in this global conversation."
Springer Nature has been at the forefront of advancing responsible research assessment. The company is a signatory of the San Francisco Declaration on Research Assessment (DORA), a member of the Coalition for Advancing Research Assessment (CoARA), and continues to promote practices that foster research integrity, open science, and transparency.
In India, Springer Nature is further supporting national efforts such as One Nation One Subscription (ONOS) and working closely with universities and research institutions to build capacity around responsible research evaluation. The company is also engaging with policymakers to ensure that global advances in research assessment translate into impactful, local change.
The survey also revealed:
Despite the emphasis on quantitative metrics, Indian researchers were more likely to report that they are evaluated on their contributions to both the national good (50%) and to solving global challenges such as those embodied in the Sustainable Development Goals (34%) than researchers in Europe (30% and 19% respectively), North America (35% and 16% respectively) or globally (40% and 25% respectively).
There is a strong desire in India for balanced assessments, blending measurable outputs with qualitative indicators such as societal relevance, collaboration, and contributions to the SDGs.
Transparency and clarity in assessment processes were rated highly by Indian respondents, indicating the importance of trust and fairness in research careers.
This growing awareness among Indian researchers aligns with Springer Nature's global push for research systems that are not only rigorous and reproducible but also fair, inclusive, and meaningful.
About Springer Nature:
Springer Nature is one of the leading publishers of research in the world. We publish the largest number of journals and books and are a pioneer in open research. Through our leading brands, trusted for more than 180 years, we provide technology-enabled products, platforms and services that help researchers to uncover new ideas and share their discoveries, health professionals to stay at the forefront of medical science, and educators to advance learning. We are proud to be part of progress, working together with the communities we serve to share knowledge and bring greater understanding to the world. For more information, please visit about.springernature.com and @SpringerNature.
Logo - https://mma.prnewswire.com/media/2578536/5362419/Springer_Nature_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/indian-researchers-call-for-balanced-and-responsible-research-assessments-springer-nature-survey-reveals-global-insights-302478792.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
Obesity Linked to Earlier Disease, Higher Comorbidity Risk
Compared with individuals with normal BMI, those with obesity have earlier onset and higher rates of related comorbidities, with musculoskeletal pain as the most common. METHODOLOGY: Obesity is associated with more than 200 comorbidities, yet limited data exist on their timing and sequence of onset. Researchers conducted a retrospective cohort study using US electronic health record data to compare the prevalence, incidence, and sequence of obesity-related comorbidities in adults with obesity (BMI ≥ 30) vs those with normal BMI (18.5 to < 25) between January 2011 and December 2014. The prevalence of 19 obesity-related comorbidities, including musculoskeletal pain and cardiometabolic and endocrine disorders, was assessed at baseline; the incidence of new-onset cases was analyzed over a median follow-up of 5 years. TAKEAWAY: Researchers included 57,978 adults each (mean age, 52 years; 64.7% women) in the cohorts with obesity and normal BMI. At baseline, 61.1% of individuals with obesity and 49.6% of those with normal BMI had at least one obesity-related comorbidity. Multimorbidity (at least three comorbidities) was nearly twice as prevalent in the obesity group vs the normal BMI group (31.2% vs 16.6%). Individuals with obesity had a significantly higher risk of developing a new obesity-related comorbidity (adjusted hazard ratio, 1.35; P < .0001). < .0001). Musculoskeletal pain was the most prevalent comorbidity at baseline and the most frequent new comorbidity in both cohorts, with a higher incidence among those with obesity (244.6 vs 197.9 per 1000 person-years). Those with obesity developed their first comorbidity at a median of 0.67 years earlier than those with normal BMI ( P < .0001), with similarly significant accelerations in the onset of second and third comorbidities. IN PRACTICE: 'Early identification and effective interventions to manage obesity should be the focus for preventing [obesity-related comorbidities], with the overall goal of reducing the burden of disease and simplifying treatment approaches,' the study authors wrote. SOURCE: This study was led by Firas Dabbous, Evidera Inc., Wilmington, North Carolina, and published online in Clinical Obesity . LIMITATIONS: Most participants were White, women, and from the US Midwest, limiting generalizability. The 5-year follow-up may not capture potential comorbidities with longer latent periods, such as cancer. Inclusion of patients taking antiobesity medications may also complicate interpretation of the results. DISCLOSURES: This study received funding from Novo Nordisk Inc. Six authors are employees and shareholders of the funding agency, and one is a consultant. Three authors are employees of Evidera Inc., which received funding from Novo Nordisk Inc.
Entrepreneur
5 hours ago
- Entrepreneur
Iom Bioworks Raises INR 4 Crore in Seed Round to Advance Microbiome-Based Healthcare
Iom Bioworks aims to personalize health by analyzing and modulating key gut bacteria to support digestion, immunity, metabolism, and overall well-being You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Iom Bioworks, a science-driven healthtech startup focused on microbiome-centered wellness, has raised INR 4 crore in Seed Round funding, led by Inflection Point Ventures (IPV). According to a press release by the company, the capital will be used to ramp up marketing efforts, secure intellectual property, build infrastructure, and expand both scientific and commercial teams. Founded in 2022, Iom Bioworks aims to personalize health by analyzing and modulating key gut bacteria to support digestion, immunity, metabolism, and overall well-being. The company's approach integrates artificial intelligence with microbiome science to offer precise and actionable health recommendations. It claims two granted patents and two more nearing completion, with scientific findings published in peer-reviewed journals. Within its first year, the company crossed 500 customers and established logistics infrastructure and digital access across India for its microbiome services. "Iom Bioworks envisions a world where a healthy mind and body are achievable through informed choices that nurture the microbiome," said Bipin Pradeep Kumar, co-founder and CEO. "By empowering our inner ecosystem through prebiotics and a food and lifestyle centred around the bacteria, we aim to energize daily life while preserving the joy of living." Kumar credited the role of their investment partner in supporting the company's growth. "Partnering with IPV has been transformative; their supportive and diligent approach has set us firmly on the path toward this vision," he added. The startup's scientific leadership includes co-founder and chief of science & technology Dr. Samik Ghosh, who leverages computational biology to develop targeted wellness solutions, and Dr. Hiroaki Kitano, co-founder and chief of research & collaboration, an internationally recognized systems biologist and AI researcher. Vinay Bansal, founder of IPV, pointed to the growing relevance of gut health in addressing chronic conditions. "Lifestyle diseases have been on the rise due to multiple reasons like poor diet, stress, lack of sleep and are intimately linked to poor gut health and microbial composition," he said. "Iom Bioworks is making this cutting-edge science accessible, personalised and importantly, actionable."
Medscape
5 hours ago
- Medscape
Novel Lyme Disease Vaccine Effective Across All Ages
An investigational vaccine for Lyme borreliosis, VLA15, was safe, well-tolerated, and immunogenic in people aged between 5 and 65 years, with children and adolescents showing notably stronger responses than adults. METHODOLOGY: Researchers assessed the safety and immunogenicity of the Lyme borreliosis vaccine candidate VLA15, administered using different vaccination schedules, in an ongoing randomized phase 2 trial conducted across multiple sites in Lyme borreliosis-endemic regions of the US. They enrolled 625 participants (median age at screening, 23 years; 51% women), including children (5-11 years), adolescents (12-17 years), and adults (18-65 years). Participants within each age cohort were randomly assigned to receive either VLA15 (180 µg) at months 0, 2, and 6 (three-dose regimen); VLA15 at months 0 and 6 with placebo at month 2 (two-dose regimen); or placebo at months 0, 2, and 6. The primary immunogenicity endpoint was the immunoglobulin G (IgG) response against outer surface protein A (OspA), measured using an enzyme-linked immunosorbent assay, at month 7 post-vaccination (1 month after the final vaccine dose) across all age cohorts. The primary safety endpoint was the frequency of solicited local and systemic adverse events within 7 days after any vaccination. TAKEAWAY: OspA-specific IgG geometric mean titers at month 7 were significantly higher in both VLA15 groups than in the placebo group ( P < .0001), with the three-dose regimen group showing higher titers (333.2-656.0 units/mL) than the two-dose regimen group (197.3-460.3 units/mL). < .0001), with the three-dose regimen group showing higher titers (333.2-656.0 units/mL) than the two-dose regimen group (197.3-460.3 units/mL). Immune responses showed an age-specific pattern, with geometric mean titers from the three-dose regimen being highest in children (706.6-1364.1 units/mL), followed by adolescents (514.6-909.5 units/mL) and adults (201.6-419.3 units/mL). Similar trends were observed with the two-dose regimen. Although antibody levels waned between months 7 and 12 in both VLA15 groups, they remained above baseline, with age-dependent patterns persisting. Solicited local and systemic adverse events were more common in the VLA15 group, though none were of grade 4. No deaths were reported during the 12-month duration of the trial. IN PRACTICE: 'VLA15 represents an important advance in the prevention of Lyme borreliosis. It covers a broad spectrum of serotypes and has a favorable safety profile in both children and adults,' the authors of a commentary wrote. SOURCE: This study was led by Laura Wagner, Valneva Austria, Vienna, Austria. It was published online on April 25, 2025, in The Lancet Infectious Diseases . LIMITATIONS: This trial had limited racial diversity, was conducted exclusively at sites in the US, and excluded individuals older than 65 years. DISCLOSURES: This study was funded by Pfizer and Valneva. Few authors reported being current or former employees or paid consultants of Valneva, with possible stock or stock option holdings. One author reported being a former employment at Pfizer, with possible stock or stock option holdings.
